The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancer
Zev A. Wainberg, MD from the University of California Medical Centre, CA, USA summarises the results of the KEYNOTE-059 Update study in patients with pre-treated metastatic gastric cancer. Presented at the ESMO 2017 Congress in Madrid, Spain, Pembrolizumab has shown a promising response rate. The expected survival of patients with metastatic gastric cancer is less than one year and very few new drugs have been approved for this disease in the past decade. The phase II KEYNOTE-059 is one of the largest studies to investigate immunotherapy in recurrent or metastatic gastric cancer and is an important study for gastric cancer, where new treatments are desperately needed. Watch the video to find out more. Recorded during the ESMO 2017 Congress.
